Reviva Pharmaceuticals Warrants
RVPHW
RVPHW was delisted on the 12th of December, 2025.
5 hedge funds and large institutions have $181K invested in Reviva Pharmaceuticals Warrants in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.06% less ownership
Funds ownership: 0.95% → 0.89% (-0.06%)
6% less capital invested
Capital invested by funds: $192K → $181K (-$11.2K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
Arena Investors
Purchase,
New York
| $83.3K | – | – | – |
|
2
Walleye Capital
New York
| $54.3K | – | – | – |
|
3
Walleye Trading
New York
| $41K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $1.67K | +$1.67K | +1,670 | New |
|
|
NC
5
NewSquare Capital
Newtown Square,
Pennsylvania
| $500 | – | – | – |
|
|
VF
6
Virtu Financial
New York
| – | -$13K | -13,091 | Closed |
|
RVPHW Hedge Fund Activity: Q1 2023 in Review
5 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q1 2023, worth a combined $181K — down 5.8% from $192K a quarter earlier.
Fund positioning in RVPHW was balanced in Q1 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $1.67K. The largest seller was Virtu Financial, exiting entirely with an estimated $13K sold.
- 5 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $181K of Reviva Pharmaceuticals Warrants stock for Q1 2023, down 5.8% quarter-over-quarter.
- 1 fund opened new Reviva Pharmaceuticals Warrants positions in Q1 2023 and 1 closed out, a net change of 0 holders.
- The largest Reviva Pharmaceuticals Warrants buyer in Q1 2023 was UBS Group, an estimated $1.67K added.
- The largest Reviva Pharmaceuticals Warrants seller in Q1 2023 was Virtu Financial, an estimated $13K sold.
Based on aggregated 13F filings for Q1 2023.